Neurofibromin, ELISA Kit

Neurofibromin; Neurofibromatosis-related protein NF-1; NF1

For Research Use Only. Not for use in diagnostic procedures.

For long term storage, please store the entire kit at -20 degree C.

Select online data sheet information is drawn from bioinformatics databases, occasionally resulting in ambiguous or non-relevant product information. It is the responsibility of the customer to review, verify, and evaluate the information to make sure it matches their requirements before purchasing the kit. Our ELISA Kit assays are dynamic research tools and sometimes they may be updated and improved. If the format of this assay is important to you then please request the current manual or contact our technical support team with a presales inquiry before placing an order. We will confirm the current details of the assay. We cannot guarantee the sample manual posted online is the most current manual.

Small volumes of NF1 elisa kit vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

MBS2883372 is a ready-to-use microwell, strip plate ELISA (enzyme-linked immunosorbent assay) Kit for analyzing the presence of the Neurofibromin (NF1) ELISA Kit target analytes in biological samples. The concentration gradients of the kit standards or positive controls render a theoretical kit detection range in biological research samples containing NF1. The ELISA analytical biochemical technique of the MBS2883372 kit is based on NF1 antibody-NF1 antigen interactions (immunosorbency) and an HRP colorimetric detection system to detect NF1 antigen targets in samples. The ELISA Kit is designed to detect native, not recombinant, NF1. Appropriate sample types may include undiluted body fluids and/or tissue homogenates, secretions. Quality control assays assessing reproducibility identified the intra-assay CV (%) and inter-assay CV(%).

318,992 Da

neurofibromin 1

neurofibromin

Neurofibromin

NF1_HUMAN

This gene product appears to function as a negative regulator of the ras signal transduction pathway. Mutations in this gene have been linked to neurofibromatosis type 1, juvenile myelomonocytic leukemia and Watson syndrome. The mRNA for this gene is subject to RNA editing (CGA>UGA->Arg1306Term) resulting in premature translation termination. Alternatively spliced transcript variants encoding different isoforms have also been described for this gene. [provided by RefSeq, Jul 2008]

NF1: a Ras-GAP, highly expressed in developing neural cells. Possesses tumor suppressor activity, presumably by virtue of its GTPase activating domain. Neurofibromin is phosphorylated in response to EGF in CNS cells and cell lines. Defects in NF1 are the cause of type 1 neurofibromatosis (NF1), Watson syndrome, and familial spinal neurofibromatosis. NF1 is one of the most frequent autosomal dominant diseases. Four alternatively spliced isoforms have been described.

Protein type: GAPs; Motility/polarity/chemotaxis; GAPs, Ras; Tumor suppressor; Nucleolus

Chromosomal Location of Human Ortholog: 17q11.2

Cellular Component: axon; cytoplasm; cytosol; dendrite; membrane; nucleolus; nucleus

Molecular Function: GTPase activator activity; phosphatidylcholine binding; phosphatidylethanolamine binding; protein binding

Biological Process: actin cytoskeleton organization and biogenesis; activation of MAPKK activity; adrenal gland development; amygdala development; artery morphogenesis; axon guidance; brain development; camera-type eye morphogenesis; cell communication; cerebral cortex development; cognition; collagen fibril organization; epidermal growth factor receptor signaling pathway; extracellular matrix organization and biogenesis; fibroblast growth factor receptor signaling pathway; forebrain astrocyte development; forebrain morphogenesis; heart development; induction of apoptosis via death domain receptors; innate immune response; insulin receptor signaling pathway; liver development; MAPKKK cascade; metanephros development; myelination in the peripheral nervous system; negative regulation of angiogenesis; negative regulation of astrocyte differentiation; negative regulation of cell migration; negative regulation of cell-matrix adhesion; negative regulation of endothelial cell proliferation; negative regulation of fibroblast proliferation; negative regulation of MAP kinase activity; negative regulation of MAPKKK cascade; negative regulation of neuroblast proliferation; negative regulation of neurotransmitter secretion; negative regulation of oligodendrocyte differentiation; negative regulation of osteoclast differentiation; negative regulation of protein kinase activity; negative regulation of Rac protein signal transduction; negative regulation of Ras protein signal transduction; negative regulation of transcription factor import into nucleus; nerve growth factor receptor signaling pathway; neural tube development; osteoblast differentiation; peripheral nervous system development; phosphoinositide 3-kinase cascade; pigmentation; positive regulation of adenylate cyclase activity; positive regulation of apoptosis; positive regulation of endothelial cell proliferation; positive regulation of GTPase activity; positive regulation of neuron apoptosis; Ras protein signal transduction; regulation of angiogenesis; regulation of blood vessel endothelial cell migration; regulation of bone resorption; regulation of cell-matrix adhesion; regulation of gene expression; regulation of glial cell differentiation; regulation of GTPase activity; regulation of long-term neuronal synaptic plasticity; regulation of synaptic transmission, GABAergic; response to hypoxia; Schwann cell development; skeletal muscle development; small GTPase mediated signal transduction; smooth muscle development; spinal cord development; sympathetic nervous system development; vascular endothelial growth factor receptor signaling pathway; visual learning; wound healing

Disease: Juvenile Myelomonocytic Leukemia; Neurofibromatosis, Familial Spinal; Neurofibromatosis, Type I; Neurofibromatosis-noonan Syndrome; Watson Syndrome

All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.

While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.

It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.